Development of the First-in-Class Degrader of NLRP3

Michael Gütschow,Tim Keuler,Jonas Engelhardt,Dominic Ferber,Christian Steinebach,Michael Marleaux,Günther Weindl,Matthias Geyer

DOI: https://doi.org/10.26434/chemrxiv-2024-0z10j

2024-11-22

Abstract:Targeted protein degradation, spearheaded by proteolysis targeting chimeras (PROTACs), has emerged as an auspicious avenue for drug discovery. NLRP3, a key player in innate immunity associated with several inflammatory diseases, has not yet been targeted by PROTACs. This study explores NLRP3 PROTACs as potential therapeutic candidates. We exploited the diaryl sulfonylurea pharmacophore and utilized a thiophene analog of the NLRP3 inhibitor MCC950 for PROTAC assembly. Using CuAAC chemistry, heterobifunctional degraders bearing various linkers and recruiting three different E3 ligases were synthesized. The compounds were evaluated in bidirectional thermal stability assays with NLRP3 and E3 ligases and their cellular activity was determined by assessing IL-1β release and protein abundance of NLRP3, respectively. PROTAC V2 induces a significant VHL-dependent degradation of NLRP3 and constitutes a valuable tool compound for future biomedical research to decipher the intricate details of the NLRP3 inflammasome.

Chemistry

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop the first PROTAC (proteolysis - targeting chimeras) molecule targeting NLRP3 protein. NLRP3 is a protein that plays a crucial role in innate immunity and is associated with various inflammatory diseases. However, there is no literature report on using PROTAC technology to target NLRP3 so far. By designing and synthesizing a series of NLRP3 PROTAC molecules, this paper aims to explore the possibility of these molecules as potential therapeutic candidates, especially their degradation effects on NLRP3 protein at the cellular level. Specifically, the researchers utilized the diarylsulfonylurea pharmacophore and adopted the thiophene analogue of NLRP3 inhibitor MCC950 for PROTAC assembly. Through CuAAC (copper - catalyzed azide - alkyne cycloaddition) chemical method, heterobifunctional degraders with different linkers were synthesized and three different E3 ubiquitin ligases were recruited. These compounds were evaluated in a two - way thermal stability test, and their cellular activities were determined by detecting IL - 1β release and NLRP3 protein abundance. The study found that compound V2 can significantly induce VHL (von Hippel - Lindau protein) - dependent NLRP3 degradation, which makes V2 a valuable tool compound for analyzing the complex details of NLRP3 inflammasome in future biomedical research.

Development of the First-in-Class Degrader of NLRP3

Degrading the key component of the inflammasome: Development of an NLRP3 PROTAC

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1

Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

Leveraging dual-ligase recruitment to enhance degradation via a heterotrivalent PROTAC

Identification of KLHDC2 as an efficient proximity-induced degrader of K-RAS, STK33, β-catenin, and FoxP3

Design and characterization of a heterobifunctional degrader of KEAP1

Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders

From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation

Discovery of Autophagy-tethering Compounds As Potent NLRP3 Degraders for IBD Immunotherapy

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Probing class I histone deacetylases (HDAC) with proteolysis targeting chimera (PROTAC) for the development of highly potent and selective degraders

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

A Degron Blocking Strategy Towards Improved CRL4CRBN Recruiting PROTAC Selectivity

Design, synthesis, and biological evaluation of Wee1 kinase degraders

Discovery and Characterization of Active CBP/EP300 Degraders Targeting the HAT Domain

Discovery of novel protein degraders based on bioorthogonal reaction-driven intracellular self-assembly strategy

Targeted protein degradation: expanding the toolbox